257 related articles for article (PubMed ID: 18971221)
1. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders.
Petereit HF; Rubbert-Roth A
Mult Scler; 2009 Feb; 15(2):189-92. PubMed ID: 18971221
[TBL] [Abstract][Full Text] [Related]
2. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
Monson NL; Cravens PD; Frohman EM; Hawker K; Racke MK
Arch Neurol; 2005 Feb; 62(2):258-64. PubMed ID: 15710854
[TBL] [Abstract][Full Text] [Related]
3. An open label study of the effects of rituximab in neuromyelitis optica.
Cree BA; Lamb S; Morgan K; Chen A; Waubant E; Genain C
Neurology; 2005 Apr; 64(7):1270-2. PubMed ID: 15824362
[TBL] [Abstract][Full Text] [Related]
4. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC
Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948
[TBL] [Abstract][Full Text] [Related]
5. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
[TBL] [Abstract][Full Text] [Related]
6. Immune surveillance in multiple sclerosis patients treated with natalizumab.
Stüve O; Marra CM; Jerome KR; Cook L; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Hemmer B; Monson NL; Racke MK
Ann Neurol; 2006 May; 59(5):743-7. PubMed ID: 16634029
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid levels of iodothyronines and nerve growth factor in patients with multiple sclerosis and neuromyelitis optica.
Jiang Y; Yang Y; Zhang B; Peng F; Bao J; Hu X
Neuro Endocrinol Lett; 2009 Mar; 30(1):85-90. PubMed ID: 19300400
[TBL] [Abstract][Full Text] [Related]
8. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab.
Pellkofer HL; Suessmair C; Schulze A; Hohlfeld R; Kuempfel T
Mult Scler; 2009 Aug; 15(8):1006-8. PubMed ID: 19667025
[TBL] [Abstract][Full Text] [Related]
9. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
Jacob A; Weinshenker BG; Violich I; McLinskey N; Krupp L; Fox RJ; Wingerchuk DM; Boggild M; Constantinescu CS; Miller A; De Angelis T; Matiello M; Cree BA
Arch Neurol; 2008 Nov; 65(11):1443-8. PubMed ID: 18779415
[TBL] [Abstract][Full Text] [Related]
10. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
[TBL] [Abstract][Full Text] [Related]
11. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Travelstead AL; Barbosa J; Bergamini RA; Civitello L; Franz DN; Greffe BS; Hanson RD; Hurwitz CA; Kalinyak KA; Kelfer H; Khakoo Y; Mantovani JF; Nicholson SH; Sanders JM; Wegner S
J Pediatr Hematol Oncol; 2006 Sep; 28(9):585-93. PubMed ID: 17006265
[TBL] [Abstract][Full Text] [Related]
12. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
Jarius S; Aboul-Enein F; Waters P; Kuenz B; Hauser A; Berger T; Lang W; Reindl M; Vincent A; Kristoferitsch W
Brain; 2008 Nov; 131(Pt 11):3072-80. PubMed ID: 18945724
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in a patient with multiple sclerosis--effect on B cells, plasma cells and intrathecal IgG synthesis.
Petereit HF; Moeller-Hartmann W; Reske D; Rubbert A
Acta Neurol Scand; 2008 Jun; 117(6):399-403. PubMed ID: 18031564
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.
Pellkofer HL; Krumbholz M; Berthele A; Hemmer B; Gerdes LA; Havla J; Bittner R; Canis M; Meinl E; Hohlfeld R; Kuempfel T
Neurology; 2011 Apr; 76(15):1310-5. PubMed ID: 21482945
[TBL] [Abstract][Full Text] [Related]
15. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success.
Greenberg BM; Graves D; Remington G; Hardeman P; Mann M; Karandikar N; Stuve O; Monson N; Frohman E
Mult Scler; 2012 Jul; 18(7):1022-6. PubMed ID: 22261118
[TBL] [Abstract][Full Text] [Related]
16. B cells as therapeutic targets in autoimmune neurological disorders.
Dalakas MC
Nat Clin Pract Neurol; 2008 Oct; 4(10):557-67. PubMed ID: 18813230
[TBL] [Abstract][Full Text] [Related]
17. B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica and multiple sclerosis.
Zhang H
Mult Scler; 2011 May; 17(5):639-40; author reply 641. PubMed ID: 21382861
[No Abstract] [Full Text] [Related]
18. A case of longitudinally extensive transverse myelitis (LETM): neuromyelitis optica.
Mangat P; Ravindran J; Cleland L; Limaye V
Clin Rheumatol; 2008 Dec; 27 Suppl 2():S67-9. PubMed ID: 18560921
[TBL] [Abstract][Full Text] [Related]
19. Specific central nervous system recruitment of HLA-G(+) regulatory T cells in multiple sclerosis.
Huang YH; Zozulya AL; Weidenfeller C; Metz I; Buck D; Toyka KV; Brück W; Wiendl H
Ann Neurol; 2009 Aug; 66(2):171-83. PubMed ID: 19705413
[TBL] [Abstract][Full Text] [Related]
20. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Piccio L; Naismith RT; Trinkaus K; Klein RS; Parks BJ; Lyons JA; Cross AH
Arch Neurol; 2010 Jun; 67(6):707-14. PubMed ID: 20558389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
